# Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors

> **NCT07702955** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Kangabio AUSTRALIA LTD PTY** · enrollment: 85 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** KGX105 injection

## Key facts

- **NCT ID:** NCT07702955
- **Lead sponsor:** Kangabio AUSTRALIA LTD PTY
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-09
- **Final completion:** 2028-11
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07702955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07702955, "Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07702955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*